YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first nine months of the fiscal year ended March 31, 2024, before the U.S. market opens on Friday, April 19, 2024.
马里兰州盖瑟斯堡,2024 年 4 月 16 日 /PRNewswire/ — 致力于发现、开发、制造和交付用于传染病和癌症的新一代疫苗和治疗生物制剂的全球生物制药公司 YS Biopharma 有限公司(NASDAQ:YS)(“YS Biopharma” 或 “公司”)今天宣布,计划发布前九个月的财务业绩截至2024年3月31日的财政年度,即2024年4月19日星期五美国市场开盘之前。
The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, April 19, 2024 to discuss the financial results. Listeners may access the call by dialing the following numbers:
公司管理层将于美国东部时间2024年4月19日星期五上午8点举行财报电话会议,讨论财务业绩。听众可以通过拨打以下号码来接听电话:
United States Toll Free: |
1-888-346-8982 |
International: |
1-412-902-4272 |
Mainland China Toll Free: |
4001-201203 |
Canada Toll Free: |
1-855-669-9657 |
Hong Kong: |
852-301-84992 |
美国免费电话: |
1-888-346-8982 |
国际: |
1-412-902-4272 |
中国大陆免费电话: |
4001-201203 |
加拿大免费电话: |
1-855-669-9657 |
香港: |
852-301-84992 |
Upon dialing-in, participants should ask to be joined into the YS Biopharma Co., Ltd. call.
拨入后,参与者应要求加入YS Biopharma有限公司的电话会议。
The replay will be accessible through April 26, 2024 by dialing the following numbers:
拨打以下号码可在 2024 年 4 月 26 日之前观看重播:
United States Toll Free: |
1-877-344-7529 |
International: |
1-412-317-0088 |
Canada Toll Free: |
1-855-669-9658 |
Access Code: |
2468327 |
美国免费电话: |
1-877-344-7529 |
国际: |
1-412-317-0088 |
加拿大免费电话: |
1-855-669-9658 |
访问码: |
2468327 |
A live and archived webcast of the conference call will also be available at the Company's investor relations website at
电话会议的网络直播和存档网络直播也将在公司的投资者关系网站上公布
About YS Biopharma
关于 YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit .
YS Biopharma是一家全球生物制药公司,致力于发现、开发、制造和商业化用于传染病和癌症的新一代疫苗和治疗性生物制剂。它开发了专有的PIKA免疫调节技术平台和一系列预防和治疗生物制剂,有可能改进狂犬病、冠状病毒、乙型肝炎、流感和带状疱疹疫苗。YS Biopharma在中国、美国、新加坡和菲律宾开展业务,由管理团队领导,该团队结合了丰富的本地专业知识和生物制药行业的全球经验。欲了解更多信息,请访问。
Investor Relations Contact
投资者关系联系人
Alyssa Li
Director of Investor Relations
Email: [email protected]
Alyssa Li
投资者关系董事
电子邮件:[电子邮件保护]
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: [email protected]
杨罗宾
ICR, LLC 合伙人
电话:+1 (212) 537-4035
电子邮件:[电子邮件保护]
SOURCE YS Biopharma Co., Ltd.
来源 YS Biopharma Co., Ltd.